Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728726 · ClinicalTrials.gov registry record · Phase 4
Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 260
- Enrollment target
NCT02728726: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT02728726 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 260 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728726, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 260 participants
- Enrollment target
Study Summary
The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
Primary Outcome
The number of subjects who have a MV as defined as \[MV \<80% MV predicted (MVPRED) based on Body Surface Area\]. MV (or respiratory minute volume or minute volume) is the volume of gas inhaled (inhaled minute volume) or exhaled (exhaled minute volume) from a person's lungs per minute.
Interventions
- DRUG Placebo
- DRUG Sugammadex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
What the finished NCT02728726 record still lists
NCT02728726 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02728726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02728726 about?
NCT02728726 is a clinical study titled "Sugammadex vs Placebo to Prevent Residual Neuromuscular Block". The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
What is the current status of trial NCT02728726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2016-06. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02728726?
The interventions under investigation include: Placebo (DRUG), Sugammadex (DRUG).
Who is sponsoring clinical trial NCT02728726?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02728726's enrollment target sits among peer trials
260 326th of 2000 higher than 1,670 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia